Management

Redoxis is a privately held company owned by founders, personnel and the investment firm Sätila MedTech AB.

Board of Directors

Rikard Holmdahl

Chairman

Professor Rikard Holmdahl (PhD, MD) has been a professor of medical inflammation research since 1993 (Karolinska Institute, Stockholm since 2008 and Lund University from 1993 to 2007). He has been a professor at the Finnish Academy (Turku University) since 2006. Dr. Holmdahl has a long experience in both academic and entrepreneurial work. He has been leading the work to standardise animal models for autoimmune diseases in Europe and has published more than 500 papers with a strong emphasis on experimental animal work. He is currently a member also of the board of Redoxis subsidiary ProNoxis AB and Vacara AB.

Malin Hultqvist Hopkins, PhD

CEO, Member of the board

Dr. Malin Hultqvist Hopkins is since May 2016 CEO of Redoxis. Malin holds a PhD in Medical Inflammation Research from Lund University (Sweden) and was between 2009-2016 CSO of Redoxis and director of CRO services. Malin is also member of the board of Redoxis subsidiary ProNoxis AB, focusing on development of small molecule drugs for treatment of autoimmune conditions.

Peter Olofsson, MBA, PhD

Member of the Board

Dr. Peter Olofsson was between 2007 and April 2016 CEO of Redoxis AB. Peter holds a PhD from Lund University and an executive MBA from the Göteborg School of Economics and Law and has previously held research positions at companies such as Arexis AB and Biovitrum AB (publ). Dr Olofsson also holds a research affiliation at the Karolinska Institute in Stockholm and engaged as external business advisor at Sahlgrenska Science Park. Since May 2016, Dr. Olofsson is the CEO and a member of the board of Redoxis subsidiary ProNoxis AB, focusing on development of small molecule drugs for treatment of autoimmune conditions.

Erik Walum

Member of the board

Erik Walum is a former professor in Neurotoxicology at Stockholm University and has served as Head of Molecular Biology and Genomics at Pharmacia and Head of Obesity Pharmacology at Biovitrum. He is presently CEO of Glucox Biotech AB.

External Funding

Redoxis is a member of several programs supported by EU integrated FP7 programs. The EU funded projects are important to us allowing networking and keeping up to date with cutting edge researchers from Europe’s main universities, clinical centers and the pharma industry.

From 2015, Redoxis was also granted EUREKA status and received Eurostars funding. The Eurostars funding is supporting improvement in technical competence and will enable growth and increased capacities.